Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 28.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 67,054 shares of the company’s stock after selling 26,430 shares during the quarter. Russell Investments Group Ltd.’s holdings in Moderna were worth $6,648,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Arlington Trust Co LLC increased its holdings in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the last quarter. Archer Investment Corp increased its stake in Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after acquiring an additional 222 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after purchasing an additional 175 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Moderna by 408.3% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company’s stock worth $63,000 after purchasing an additional 490 shares during the period. Finally, Sound Income Strategies LLC lifted its stake in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Moderna news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the sale, the director now directly owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. In the last ninety days, insiders sold 139,954 shares of company stock worth $14,822,576. 15.20% of the stock is currently owned by insiders.

Moderna Price Performance

Shares of MRNA stock opened at $121.89 on Thursday. The firm has a fifty day moving average of $106.59 and a two-hundred day moving average of $95.24. The firm has a market cap of $46.71 billion, a P/E ratio of -7.78 and a beta of 1.57. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same period last year, the firm earned $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. As a group, research analysts anticipate that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on MRNA shares. Royal Bank of Canada raised their price target on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. HSBC restated a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Canaccord Genuity Group increased their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $126.89.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.